Your bridge to Europe and US life sciences.
We help Chinese life science companies plan European and US market entry, connecting regulatory strategy, clinical development, quality and evidence planning under one accountable founder.
A clear plan from Chinese innovation to European and US markets.
European and US pathways differ in their evidence requirements, agency procedures and payer expectations. We help China-based teams understand those differences, assess their existing data and plan the work needed for their product.
One founder leads your engagement, connecting regulatory, clinical, quality and medical evidence questions within an agreed scope. Quality and payer-evidence planning start early, alongside the regulatory strategy.
About Kaiveo MedicalOne integrated partner
Regulatory, clinical, quality and evidence planning follow one coordinated roadmap, with clear responsibilities and decisions shared across workstreams.
Depth in both systems
Hands-on experience informs our assessment of EU and FDA requirements, from clinical trial applications and medicines dossiers to quality and device pathways. Each engagement is matched to the expertise it needs.
Fluent in both worlds
We explain scientific and regulatory expectations in the context of your programme. Language support is agreed for each engagement.
Four disciplines. One pathway, two markets.
Engage a single service or a coordinated programme. Every engagement has one accountable founder as lead, with scope, schedule and language support agreed before work begins.
Regulatory Affairs
Chart the right route to approval in Europe or the United States, from pathway selection to agency dialogue and dossier submission.
- EU and FDA regulatory strategy & pathway selection
- Scientific advice & agency interactions
- CTD/eCTD & technical documentation
- Lifecycle & variations management
Clinical Research Management
Plan studies around EU and FDA expectations, with proportionate budgets, carefully selected sites and sponsor oversight.
- EU and US clinical development planning
- Study design, endpoints and comparators
- CRO & vendor selection and oversight
- Site feasibility & study management
Quality & Compliance
Prepare your sites, suppliers and quality system for applicable European and US requirements.
- QMS design (EU GMP, ISO 13485, QMSR)
- Audit & inspection readiness
- Supplier & CDMO qualification
- Compliance remediation
Clinical & Medical Affairs
Plan the evidence questions that matter to clinicians and payers, from development through launch.
- Medical strategy & evidence planning
- Scientific and payer evidence gaps
- Evidence and scientific communication planning
- Post-market evidence requirements
A structured path from first assessment to growth in both markets.
Five stages, one coordinated roadmap. Quality, risk management and payer-evidence planning run across the stages. Select a stage to explore the work and its intended deliverables.
Know the route before you commit the budget.
We review your product, data, manufacturing arrangements and target markets. Regulatory options, quality gaps and clinical or payer-evidence questions are assessed together, so the roadmap reflects the work, budget assumptions and risks specific to your programme.
What you receive
- Market & competitor landscape, both regions
- Regulatory gap analysis of your existing package
- Country prioritisation & sequencing
- Integrated budget, timeline & risk register
Choose the pathway and build the case for it.
For medicines, we distinguish EU clinical trial applications from marketing authorisation routes, and US INDs from full NDAs, 505(b)(2) NDAs, ANDAs and BLAs. For devices and IVDs, we assess the applicable conformity or FDA route. Briefing documents, agency preparation and an evidence-gap plan support the selected strategy.
What you receive
- Regulatory strategy & procedure selection
- Scientific advice / notified body briefing packages
- CTA / IND, eCTD or technical documentation gap plan
- Submission plan with agency interaction calendar
Build evidence for the intended regulatory pathway.
We assess study design, endpoints, comparators, populations and country options against the intended use of the data. Carefully selected CROs and sites support an agreed oversight plan. Regulatory Affairs coordinates CTA or IND submissions; device investigations and IVD performance studies follow their applicable procedures.
What you receive
- EU- and US-ready clinical development plan
- Study start-up and regulatory filing coordination
- CRO / vendor selection and contract oversight
- Data & documentation ready for review
Make quality a strength, not a risk.
Quality preparation begins during assessment and continues through development. We review applicable requirements, investigate gaps, support CAPA effectiveness and prepare staff for inspections. Where a QP, QPPV, authorised representative, PRRC or US Agent is required, responsibilities and the need for an appropriately qualified provider are identified before any appointment is agreed.
What you receive
- QMS gap assessment & remediation plan
- Mock inspections & CAPA support
- Supplier / CDMO qualification
- Specialist-role requirements and appointment planning
Approval is the beginning. Adoption is the goal.
We connect the regulatory evidence plan with clinical and payer questions early in development. Authorisation, pricing and reimbursement are separate objectives. The launch roadmap identifies scientific communication, post-market evidence and specialist support needs, with delivery responsibilities and scope agreed for the engagement.
What you receive
- Medical launch plan & scientific platform
- Clinical and payer evidence priorities
- Post-market evidence and vigilance requirements
- Lifecycle & multi-country expansion roadmap
How far does your Chinese evidence travel?
EU and US authorities assess the evidence for the application before them. We review the quality, relevance and regulatory fit of your existing Chinese data, then identify what can support the submission and where further work may be needed.
Pharma
We assess whether your Chinese CMC, non-clinical and clinical evidence can support the intended EU or FDA application, considering study quality, population relevance and the remaining gaps.
Biotech
We assess biologic and ATMP evidence, including CMC, comparability and clinical data, against the intended EU or FDA pathway and identify where further justification or development may be needed.
Medical devices & IVD
We distinguish device clinical evaluation from IVD performance evaluation, assessing whether existing data support the intended claims and identifying evidence gaps for CE marking or FDA submissions.
Built for the China–Europe–US corridor, not adapted to it.
Kaiveo Medical focuses on the practical needs of China-based teams planning European and US development. A named founder keeps the scope, priorities and responsibilities clear.
Remote, founder-led consulting
A remote consultancy with one accountable founder as your lead. Meeting arrangements, reporting and language support are agreed for each engagement.
- Remote delivery, with on-site visits by arrangement.
- Scope and schedule agreed per engagement.
End-to-end accountability
One founder coordinates the agreed work, records decisions and maintains clear responsibilities across the programme.
Relevant experience
Your engagement is matched to the relevant regulatory, clinical or quality experience, with specialist requirements identified during scoping.
Regulatory intelligence
We review relevant EU and FDA developments for the agreed scope and explain what changes may mean for your evidence, submission or quality plan.
Clear scope and delivery
From a dossier review to a coordinated market-entry programme, deliverables, availability and milestones are agreed before work begins.
Appropriate specialist support
We identify where CRO, legal, market-access or other specialist input is needed. Provider availability, qualifications and responsibilities are confirmed before appointments are made.
Specialised support for every product type.
Innovative, generic and biosimilar medicines
Pathway: Existing data → EU authorisation via EMA or national authorities; FDA NDA, ANDA or BLA. Clinical trials use separate CTA / IND pathways.
We prepare manufacturing sites for EU GMP inspection and assess dossiers against the intended EU or FDA route, including drug-led combination products. Biotechnology-derived biosimilars require the EU centralised procedure; other products are assessed for the appropriate route.
- EU MAA strategy: centralised, DCP / MRP or national routes
- EU GMP and FDA cGMP readiness for Chinese sites
- QP, import and US Agent requirements assessment
Biologics, ATMPs and novel modalities
Pathway: EU CTA / FDA IND where required → development evidence → EU or FDA marketing application.
Cell and gene therapies, antibodies, bispecifics, RNA platforms: European reviewers scrutinise novel modalities closely, and early dialogue matters. We help biotech innovators secure the right designations, engage EMA early and design clinical programmes that European regulators and clinicians trust.
- Scientific advice, orphan designation and PRIME eligibility
- ATMP-specific regulatory and GMP considerations
- First-in-human and pivotal study set-up in Europe and the US
MDR, IVDR and FDA conformity, done properly
Pathway: EU MDR / IVDR conformity assessment for CE marking; FDA 510(k) clearance, De Novo classification or PMA approval.
CE marking under the MDR and IVDR requires technical documentation, device clinical evaluation or IVD performance evaluation, and an appropriate quality system. We assess classification, conformity route, evidence gaps and post-market requirements for the specific product.
- Classification, conformity route and notified-body strategy
- Technical documentation and device / IVD evidence requirements
- ISO 13485 QMS alignment and audit readiness
Selected team experience.
Anonymised engagements from our team’s experience, showing how regulatory, clinical and quality expertise supports life science companies entering international markets.
Securing trial approval for a drug-device combination
A rejected application in France was reassessed across medicinal product and device requirements, giving a pivotal trial a route forward.
Clinical trial application approved
A clearer strategy for foreign-generated data
Targeted EU and UK scientific advice helped a sponsor understand how its existing pivotal data could inform a registration strategy.
Regulatory strategy clarified
Preparing a cell therapy site for EU GMP inspection
Evidence-based investigations, CAPA effectiveness verification and inspection rehearsals strengthened a cell therapy site’s preparation.
Inspection readiness strengthened
Perspectives on Europe and the US, written for China-based teams.
The China → Europe and US market-entry playbook: five decisions that determine your timeline
Pathway, data, legal roles, quality and sequencing. Each decision looks like paperwork and behaves like architecture.
Read articleChoosing between centralised and decentralised procedures: a decision framework for Chinese sponsors
Mandatory scope settles the question for many products. Where it does not, the choice turns on your market footprint and the Reference Member State you pick.
Read articlePreparing for a notified-body audit: what surprises non-EU manufacturers most
A notified body is not certifying your quality system as an end in itself. It is deciding whether your device may be placed on the European market.
Read articleReady to bring your innovation to European and American patients?
Tell us about your product, development stage and target markets. We can discuss the regulatory, clinical, quality and evidence questions that should shape the next step.
Add us on WeChat for a direct conversation
Check your readiness for either market.
Or start with a market-entry assessment →
We aim to reply within two working days. Language support is agreed for each engagement.
One founder leads each engagement. Specialist appointments and delivery responsibilities are scoped separately.
